水稻胚乳里的生物密码：

Investment Rating - The report rates the investment in the biopharmaceutical sector, particularly focusing on He Yuan Bio, as highly valuable due to its innovative technology and market potential [4]. Core Insights - He Yuan Bio is a leader in plant-derived recombinant protein drugs in China, utilizing unique rice endosperm cell bioreactor technology to reduce reliance on plasma. Its core product, HY1001 (recombinant human albumin), is set to be approved in China by July 2025 and is advancing through Phase III trials in the U.S. The company anticipates revenues exceeding 3 billion by 2030, supported by a production capacity of 120 tons and a global expansion strategy [4]. Company Overview - He Yuan Bio, established in 2006, specializes in the research and development of plant-derived recombinant protein expression technology. The company has developed two core technology platforms: a high-efficiency recombinant protein expression platform and a protein purification platform, achieving global leading indicators [10][18]. Product Pipeline - The core product, HY1001, is expected to be prioritized for approval in China by July 2025, targeting liver cirrhosis with low albumin levels. Other products in the pipeline include HY1002 (oral lactoferrin lysozyme) and HY1003 (α-1 antitrypsin), with various stages of clinical trials planned [5][33]. Market and Competition - The human recombinant albumin market in China is projected to grow from 39.5 billion in 2024 to 57 billion by 2030, with a CAGR of 6%. The global market (excluding China) is expected to reach 7.405 billion by 2030, with a CAGR of 6.28%. He Yuan Bio is positioned as a domestic pioneer in this market, with significant potential for import substitution [6][56]. Production and Cost Advantages - He Yuan Bio's production cost for recombinant human albumin is projected to be significantly lower than traditional plasma-derived methods, with estimates dropping to 7-10 yuan per gram at full capacity, representing a cost reduction of over 50% [73]. The company has established a commercial-scale production line capable of producing 10 tons annually and plans to expand to 120 tons [28].